Syros Pharmaceuticals (SYRS) Insider Trading & Ownership $7.79 +0.59 (+8.19%) (As of 12/29/2023 ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Syros Pharmaceuticals (NASDAQ:SYRS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage10.45%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$4.00 MNumber OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)$56,269.75 Get SYRS Insider Trade Alerts Want to know when executives and insiders are buying or selling Syros Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address SYRS Insider Buying and Selling by Quarter Syros Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/21/2023Srinivas AkkarajuDirectorBuy904,977$4.42$3,999,998.34 12/6/2023David RothInsiderSell6,287$3.95$24,833.65 7/31/2023David RothInsiderSell7,348$3.95$29,024.60 7/17/2023Eric R OlsonInsiderSell689$3.50$2,411.50 (Data available from 1/1/2013 forward) SYRS Insider Trading Activity - Frequently Asked Questions Who is on Syros Pharmaceuticals's Insider Roster? The list of insiders at Syros Pharmaceuticals includes David Roth, Eric R Olson, Richard A Young, Srinivas Akkaraju, and Timothy Tyson. Learn more on insiders at SYRS. What percentage of Syros Pharmaceuticals stock is owned by insiders? 10.45% of Syros Pharmaceuticals stock is owned by insiders. Learn more on SYRS's insider holdings. Which Syros Pharmaceuticals insiders have been buying company stock? The following insiders have purchased SYRS shares in the last 24 months: Srinivas Akkaraju ($3,999,998.34), and Timothy Tyson ($16,771.04). How much insider buying is happening at Syros Pharmaceuticals? Insiders have purchased a total of 907,909 SYRS shares in the last 24 months for a total of $4,016,769.38 bought. Which Syros Pharmaceuticals insiders have been selling company stock? The following insiders have sold SYRS shares in the last 24 months: David Roth ($53,858.25), and Eric R Olson ($10,073.26). How much insider selling is happening at Syros Pharmaceuticals? Insiders have sold a total of 16,532 Syros Pharmaceuticals shares in the last 24 months for a total of $63,931.51 sold. More Insider Trading Tools from MarketBeat Related Companies: Eton Pharmaceuticals Insider Transactions Abeona Therapeutics Insider Transactions Anixa Biosciences Insider Transactions PMV Pharmaceuticals Insider Transactions Kinnate Biopharma Insider Transactions Generation Bio Insider Transactions XBiotech Insider Transactions Ventyx Biosciences Insider Transactions Rallybio Insider Transactions Sagimet Biosciences Insider Transactions Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: Insiders bet big on these turnaround stocksLiquidia: Court victory the awakening of an industry giant?Insiders are selling into these ralliesDecember’s hot insider buys have a catalyst for higher prices3 stocks that are primed for an end-of-year Santa Claus rally This page (NASDAQ:SYRS) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.